Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Odds Ratio

Odds Ratio

The odds ratio (OR) is a statistical measure used extensively in epidemiology and research to quantify the strength of association between exposure and outcome across different groups. Unlike relative risk, which compares the probabilities of an event occurring, the odds ratio compares the odds of an event occurring in the exposed group to the odds of it occurring in the unexposed group. The odds, in this context, are calculated as the probability of the event happening divided by the...

Regression Toward the Mean

Regression Toward the Mean

Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

Hazard Ratio

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...

Observational Studies

Observational Studies

Observational studies are a type of analytical study where researchers observe events without any interventions. In other words, the researcher does not influence the response variable or the experiment's outcome.
There are three types of observational studies – Prospective, retrospective, and cross-sectional.
Prospective Study
Prospective studies, also known as longitudinal or cohort studies, are carried out by collecting future data from groups sharing similar characteristics. One...

Bioequivalence Data: Statistical Interpretation

Bioequivalence Data: Statistical Interpretation

Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Use of Baseline Score in Cost-Effectiveness Modeling of Competing Interventions.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Same author

Impact of Treatment Effect Heterogeneity on the Estimation of Individualized Treatment Rules for Count Outcomes.

Biometrical journal. Biometrische Zeitschrift·2026

Same author

A 2-stage model of heterogenous treatment effects for brain atrophy in multiple sclerosis utilizing the MS PATHS research network.

Multiple sclerosis and related disorders·2024

Same author

Combining randomized and non-randomized data to predict heterogeneous effects of competing treatments.

Research synthesis methods·2024

Same author

Visualizing the target estimand in comparative effectiveness studies with multiple treatments.

Journal of comparative effectiveness research·2024

Same author

Predictors of treatment switching in the Big Multiple Sclerosis Data Network.

Frontiers in neurology·2024

Search research articles

Related Experiment Video

Updated: Nov 11, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

Estimation and Validation of Ratio-based Conditional Average Treatment Effects Using Observational Data.

Steve Yadlowsky¹, Fabio Pellegrini², Federica Lionetto³

¹Stanford University, Electrical Engineering, 1265 Welch Rd, Stanford, 94305-6104 United States.

Journal of the American Statistical Association

|March 26, 2021

Summary

This study introduces a new method to estimate treatment effects in observational studies, crucial for precision medicine. The approach improves the analysis of treatment-covariate interactions, particularly for conditions like multiple sclerosis.

Keywords:

Conditional Average Treatment Effect Doubly Robust Estimation Heterogeneous Treatment Effect Observational Study Precision Medicine

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

Related Experiment Videos

Last Updated: Nov 11, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

Area of Science:

Biostatistics
Epidemiology
Pharmacology

Background:

Randomized clinical trials often lack sufficient sample sizes for detailed treatment-covariate interaction analysis.
Observational data offers a valuable supplement for understanding treatment effects in real-world settings.
Standard methods for analyzing observational data can introduce bias when models are misspecified.

Purpose of the Study:

To develop a robust method for estimating conditional average treatment effects (CATE) in observational studies.
To address the challenge of modeling treatment-covariate interactions for precision medicine.
To apply the method to analyze multiple sclerosis patient data.

Main Methods:

Proposed a doubly robust estimator for CATE, defined as the ratio of expected potential outcomes.
Utilized a semiparametric model for treatment-covariate interactions.
Developed a validation procedure using independent samples.

Main Results:

Simulations demonstrated the effectiveness of the proposed methods in finite samples.
The approach successfully estimated treatment-covariate interactions, outperforming simpler methods.
The method was illustrated on real-world data for multiple sclerosis treatment comparison.

Conclusions:

The proposed doubly robust estimator provides a reliable way to assess treatment-covariate interactions in observational studies.
This method enhances the potential for data-driven precision medicine by leveraging real-world data.
The findings have implications for understanding treatment efficacy in specific patient subgroups, exemplified by multiple sclerosis.